Developer docs
API playgroundTry for free, no card

Search company profiles

Medsenic

Full company profile

uuid0004rft

Namestring
Medsenic
Legal namestring
Medsenic
Websiteurl
medsenic.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Medsenic is a private drug development company headquartered in Paris, France, founded in 2010. The firm operates with a small team of 1-10 employees and is led by co-founders François Rieger (Chief Executive Officer & President) and Véronique Pomi (Chief Operating Officer). As a clinical-stage developer, Medsenic's pipeline and capabilities were significantly expanded through its October 2022 acquisition of Bone Therapeutics, a bone cell therapy company, though no specific products, therapeutic indications, or pipeline assets are publicly disclosed in the available data.

The company's only documented funding event was a February 2018 round of approximately $2.48 million, led by Investisseurs & Partenaires with participation from Cap Innov'Est and FaDièse. No subsequent funding rounds are recorded, and the company's website is currently in scheduled maintenance mode, limiting access to product, clinical, or commercial disclosures. The business model is not publicly articulated, but the headcount, funding scale, and absence of disclosed revenue are consistent with a pre-commercial drug developer relying on R&D funding and asset-based value creation rather than product sales.

Given the limited public footprint, Medsenic's strategic value appears to reside primarily in the clinical-stage assets and IP absorbed via the Bone Therapeutics transaction. The lack of publicly available product information, customer references, pricing, partnerships, or revenue signals represents a significant data gap that constrains any deeper commercial or competitive analysis.

Short descriptiontext

Medsenic is a private Paris-based drug development company founded in 2010. Led by co-founders François Rieger and Véronique Pomi, the firm operates with 1-10 employees and expanded its pipeline via its 2022 acquisition of Bone Therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStrasbourg, France
HQ citystring
Strasbourg
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
drug development, pharmaceutical research, biopharmaceutical products, clinical-stage therapeutics, pharmaceutical pipeline
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drug Development
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Medsenic is a private drug development company headquartered in Paris, France. The company focuses on pharmaceutical research and development, building its therapeutic pipeline through internal R&D and strategic acquisitions, including the 2022 acquisition of Bone Therapeutics to expand into bone-related therapeutics.

Differentiator
Functional benefit
Problem solved
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Bone Therapeutics
TypeDirect peer
Description

Belgian cell-therapy biotech that Medsenic acquired in 2022, formerly focused on bone disease and regenerative medicine. Its prior clinical assets and IP are now integrated into Medsenic, making the acquisition target itself the closest historical peer.

2Innate Pharma
TypeDirect peer
Description

France-headquartered (Marseille) clinical-stage biotech developing immuno-oncology and immunology therapies. Comparable as a small French innovator-drug developer with specialty-pharmaceutical positioning.

TypeDirect peer
Description

Paris-based clinical-stage biotech developing epicutaneous immunotherapy for allergies and autoimmune-related conditions. Comparable as a French specialty-pharmaceutical developer targeting immune-mediated diseases.

TypeDirect peer
Description

French Paris-based clinical-stage biotech developing small-molecule therapies for chronic inflammatory diseases. Comparable as a small French innovator-drug developer targeting specialty autoimmune/inflammatory indications with a lean team.

TypeEmerging player
Description

French (Marseille) clinical-stage biotech developing first-in-class gamma-delta T cell-based immunotherapies for cancer and autoimmune disease. Comparable geography and drug-development innovation model, with broader oncology focus.

6Valneva
TypeDirect peer
Description

France-headquartered specialty vaccine company developing prophylactic vaccines for infectious diseases. Comparable French specialty-innovator pharmaceutical with a small-team, focused-portfolio model.

TypeDirect peer
Description

French clinical-stage biotech developing first-in-class immunotherapies for autoimmune diseases and immuno-oncology. Comparable French specialty-pharma innovator with autoimmune focus and Paris-area presence.

TypeOthers
Description

French cell-therapy biotech formerly listed in Paris that developed antigen-specific regulatory T-cell therapies for autoimmune and inflammatory diseases. Closest historical European peer in cell-therapy for autoimmunity, now operating within Sangamo.

TypeDirect peer
Description

Paris-listed clinical-stage biotech developing gene therapies for neurodegenerative diseases of the eye and CNS. Comparable as a French, small-employee-count innovator-drug developer focused on specialty indications.

TypeDirect peer
Description

French biopharmaceutical company developing oral small-molecule therapies for metabolic, fibrotic and autoimmune diseases. Comparable geography (France), innovator-pharmaceutical model, and specialty-disease focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medsenic

Pharmaceutical Drug Developmentmedsenic.com

Medsenic is a private Paris-based drug development company founded in 2010. Led by co-founders François Rieger and Véronique Pomi, the firm operates with 1-10 employees and expanded its pipeline via its 2022 acquisition of Bone Therapeutics.

What Medsenic does

Medsenic is a private drug development company headquartered in Paris, France, founded in 2010. The firm operates with a small team of 1-10 employees and is led by co-founders François Rieger (Chief Executive Officer & President) and Véronique Pomi (Chief Operating Officer). As a clinical-stage developer, Medsenic's pipeline and capabilities were significantly expanded through its October 2022 acquisition of Bone Therapeutics, a bone cell therapy company, though no specific products, therapeutic indications, or pipeline assets are publicly disclosed in the available data.

The company's only documented funding event was a February 2018 round of approximately $2.48 million, led by Investisseurs & Partenaires with participation from Cap Innov'Est and FaDièse. No subsequent funding rounds are recorded, and the company's website is currently in scheduled maintenance mode, limiting access to product, clinical, or commercial disclosures. The business model is not publicly articulated, but the headcount, funding scale, and absence of disclosed revenue are consistent with a pre-commercial drug developer relying on R&D funding and asset-based value creation rather than product sales.

Given the limited public footprint, Medsenic's strategic value appears to reside primarily in the clinical-stage assets and IP absorbed via the Bone Therapeutics transaction. The lack of publicly available product information, customer references, pricing, partnerships, or revenue signals represents a significant data gap that constrains any deeper commercial or competitive analysis.

Medsenic firmographics

Firmographics
Name
Medsenic
Legal name
Medsenic
Website
https://medsenic.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Medsenic is a private Paris-based drug development company founded in 2010. Led by co-founders François Rieger and Véronique Pomi, the firm operates with 1-10 employees and expanded its pipeline via its 2022 acquisition of Bone Therapeutics.
Ownership category
akta.pro rank

Medsenic industry classification

Industry
Product category
Pharmaceutical Drug Development
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Drug development
  • Pharmaceutical research
  • Biopharmaceutical products
  • Clinical-stage therapeutics
  • Pharmaceutical pipeline

Where Medsenic is headquartered

Location

Headquarters

HQ city
Strasbourg
HQ country
France
HQ region
Europe

Markets served

Medsenic business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Medsenic product offering

Product offering

Core offering

Medsenic is a private drug development company headquartered in Paris, France. The company focuses on pharmaceutical research and development, building its therapeutic pipeline through internal R&D and strategic acquisitions, including the 2022 acquisition of Bone Therapeutics to expand into bone-related therapeutics.

Differentiator

Problem solved

Functional benefit

Companies that use Medsenic

Customer profile

Ideal customer profiles1 record

Medsenic technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Medsenic partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Medsenic competitors and assessment

Company assessment

Direct peers

  • Bone Therapeutics: Belgian cell-therapy biotech that Medsenic acquired in 2022, formerly focused on bone disease and regenerative medicine. Its prior clinical assets and IP are now integrated into Medsenic, making the acquisition target itself the closest historical peer.
  • Innate Pharma: France-headquartered (Marseille) clinical-stage biotech developing immuno-oncology and immunology therapies. Comparable as a small French innovator-drug developer with specialty-pharmaceutical positioning.
  • DBV Technologies: Paris-based clinical-stage biotech developing epicutaneous immunotherapy for allergies and autoimmune-related conditions. Comparable as a French specialty-pharmaceutical developer targeting immune-mediated diseases.
  • Abivax: French Paris-based clinical-stage biotech developing small-molecule therapies for chronic inflammatory diseases. Comparable as a small French innovator-drug developer targeting specialty autoimmune/inflammatory indications with a lean team.
  • Valneva: France-headquartered specialty vaccine company developing prophylactic vaccines for infectious diseases. Comparable French specialty-innovator pharmaceutical with a small-team, focused-portfolio model.
  • OSE Immunotherapeutics: French clinical-stage biotech developing first-in-class immunotherapies for autoimmune diseases and immuno-oncology. Comparable French specialty-pharma innovator with autoimmune focus and Paris-area presence.
  • GenSight Biologics: Paris-listed clinical-stage biotech developing gene therapies for neurodegenerative diseases of the eye and CNS. Comparable as a French, small-employee-count innovator-drug developer focused on specialty indications.
  • Inventiva: French biopharmaceutical company developing oral small-molecule therapies for metabolic, fibrotic and autoimmune diseases. Comparable geography (France), innovator-pharmaceutical model, and specialty-disease focus.

Emerging players

  • ImCheck Therapeutics: French (Marseille) clinical-stage biotech developing first-in-class gamma-delta T cell-based immunotherapies for cancer and autoimmune disease. Comparable geography and drug-development innovation model, with broader oncology focus.

Others

  • TxCell (acquired by Sangamo Therapeutics): French cell-therapy biotech formerly listed in Paris that developed antigen-specific regulatory T-cell therapies for autoimmune and inflammatory diseases. Closest historical European peer in cell-therapy for autoimmunity, now operating within Sangamo.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Medsenic social profiles

Digital presence

Medsenic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medsenic leadership team

Management profile

Number of profiles

Profiles2 records

Medsenic funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medsenic M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medsenic

What does Medsenic do?

Medsenic is a private drug development company headquartered in Paris, France. The company focuses on pharmaceutical research and development, building its therapeutic pipeline through internal R&D and strategic acquisitions, including the 2022 acquisition of Bone Therapeutics to expand into bone-related therapeutics.

When was Medsenic founded?

Medsenic was founded in 2010. It employs 1 to 10 people.

Where is Medsenic based?

Medsenic is headquartered in Strasbourg, France, in the Europe region.

Who are Medsenic's main competitors?

Direct peers on record are Bone Therapeutics, Innate Pharma, DBV Technologies, Abivax, Valneva, OSE Immunotherapeutics, GenSight Biologics and Inventiva. ImCheck Therapeutics is listed as an emerging player. TxCell (acquired by Sangamo Therapeutics) is listed as an others.

Does Medsenic have an API?

No public API is recorded for Medsenic.

What industry is Medsenic in?

Medsenic's product category is Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ChinaventureCell therapy is rewriting the orthopedic landscape, with giants betting heavily, and a cluster of phase II/III pipelines.Cell therapy for orthopedic conditions is advancing, with multiple pipelines entering phase II/III trials. Zhongsheng Suyuan's NCR100 injection, an iPSC-derived MSC product, completed its phase II knee osteoarthritis trial with positive efficacy signals, including cartilage growth. Investors see a patient population in tens of millions, signaling a shift toward core orthopedic treatment.GlobeNewswireMedsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosisThe European Patent Office granted a key EU patent to Medsenic for using arsenic trioxide to treat relapsing-remitting multiple sclerosis. The patent, EP18722530, covers repeated cycles of administration via multiple routes, including intravenous and oral. It supports development of phase 2-3 clinical trials for this indication.GlobeNewswireMedsenic, subsidiary of BioSenic SA, extends key patent to the United StatesBioSenic's subsidiary Medsenic filed a US patent application for using arsenic trioxide to treat sepsis syndrome. The patent family covers immune and oncology indications, including chronic GvHD and acute promyelocytic leukemia. The company plans further divisional applications and international clinical trials.European BiotechnologyBone Therapeutics merges with Medsenic and changes nameMedsenic and Bone Therapeutics merged to form BioSenic, with Medsenic shareholders contributing 51% of shares valued at €40.8 million. The combined company will target both tissue inflammation and repair, with a Phase III cGvHD study planned for H1/2023. BioSenic will remain a Belgian listed company.GlobeNewswireBone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 millionBone Therapeutics closed its acquisition of a majority stake in Medsenic, valued at EUR 40.8 million, and changed its name to BioSenic. The new company will combine its cell therapy platform with Medsenic's arsenic trioxide formulations for inflammatory diseases. A Phase III study for cGvHD is planned for H1 2023.GlobeNewswireBone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 millionBone Therapeutics acquired a majority stake in Medsenic for EUR 40.8 million, changing its name to BioSenic. The new company combines cell therapy and arsenic trioxide platforms, with a Phase III cGvHD study planned for H1 2023.GlobeNewswireBone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in MedsenicBone Therapeutics signed a binding agreement to acquire 51% of Medsenic, creating BioSenic, a specialty biopharma company. The deal values Medsenic at EUR 40.8 million and includes a subscription right for ALLOB trial results. The transaction is subject to shareholder approval in September 2022.GlobeNewswireBone Therapeutics enters into exclusive reverse merger discussions with MedsenicBone Therapeutics entered exclusive reverse merger discussions with Medsenic shareholders for a three-month period. The deal would have Medsenic shareholders contributing 51% of Medsenic's capital to Bone Therapeutics, with Medsenic shareholders expected to hold about 80% of Bone Therapeutics post-closing. The parties aim to reach an agreement in Q2/Q3 2022.BioWorldMooted reverse merger with Medsenic a lifeline for Bone TherapeuticsBone Therapeutics SA entered an exclusive three-month discussion period with Medsenic SAS, which could lead to a reverse merger. The potential transaction is a lifeline for the Belgian cell therapy developer, which is running out of cash and has been largely abandoned by shareholders.